What is Miroculus?
Founded in 2014, Miroculus has developed a proprietary digital microfluidics technology. This innovative system is designed to automate and miniaturize complex genomic protocols, including next-generation sequencing (NGS) library preparation, synthetic biology applications, cell editing, and combinatorial chemistry. The compact and user-friendly system aims to streamline laboratory workflows and accelerate research and development in the life sciences sector.
How much funding has Miroculus raised?
Miroculus has raised a total of $48.2M across 3 funding rounds:
Angel/Seed
$2.8M
Debt
$350K
Series B
$45M
Angel/Seed (2015): $2.8M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Series B (2021): $45M supported by Cota Capital and Section 32
Key Investors in Miroculus
Cota Capital
Cota Capital is an investment firm that focuses on early-stage technology companies addressing innovative challenges in the enterprise sector. They combine financial investment with deep operational expertise and industry insights to empower founders in building transformative businesses.
Section 32
Section 32 is a venture capital firm that focuses on investing in cutting-edge technology. Founded by Bill Maris, the firm is backed by a team with extensive experience in building iconic companies. Their investment strategy targets innovative startups and emerging technologies.
What's next for Miroculus?
The recent major strategic investment signals a pivotal growth phase for Miroculus. This capital infusion is expected to fuel further development of its microfluidics platform, expand its market reach, and potentially support strategic partnerships within the enterprise-level biotechnology and pharmaceutical industries. The company's focus on automating critical genomic processes positions it to capitalize on the increasing demand for efficient and scalable molecular biology solutions.
See full Miroculus company page
